Reducing the Diagnostic Heterogeneity of Schizoaffective Disorder by Katherine Seldin et al.
February 2017 | Volume 8 | Article 181
Original research
published: 10 February 2017
doi: 10.3389/fpsyt.2017.00018
Frontiers in Psychiatry | www.frontiersin.org
Edited by: 
Stefan Borgwardt, 
University of Basel, Switzerland
Reviewed by: 
Dolores Malaspina, 
New York University School of 
Medicine, USA  
Rolf-Dieter Stieglitz, 
University of Basel, Switzerland
*Correspondence:
Katherine Seldin 
katherine.seldin@vanderbilt.edu
Specialty section: 
This article was submitted to 
Psychopathology, 
a section of the journal 
Frontiers in Psychiatry
Received: 16 November 2016
Accepted: 23 January 2017
Published: 10 February 2017
Citation: 
Seldin K, Armstrong K, Schiff ML and 
Heckers S (2017) Reducing the 
Diagnostic Heterogeneity of 
Schizoaffective Disorder. 
Front. Psychiatry 8:18. 
doi: 10.3389/fpsyt.2017.00018
reducing the Diagnostic 
heterogeneity of 
schizoaffective Disorder
Katherine Seldin*, Kristan Armstrong, Max L. Schiff and Stephan Heckers
Psychiatric Neuroimaging Program, Department of Psychiatry and Behavioral Sciences, Vanderbilt University, Nashville, TN, USA
Objective: Clinical outcome studies of schizoaffective disorder patients have yielded 
conflicting results. One reason is the heterogeneity of samples drawn from the schi-
zoaffective disorder population. Here, we studied schizoaffective disorder patients 
who showed marked functional impairment and continuous signs of illness for at least 
6 months (i.e., DSM criteria B and C for schizophrenia).
Methods: We assessed 176 chronic psychosis patients with a structured interview 
(SCID-IV-TR) and the Diagnostic Interview for Genetic Studies schizoaffective disorder 
module. We diagnosed 114 patients with schizophrenia and 62 with schizoaffective 
disorder. The two groups were similar with regard to age, gender, and race. We tested 
for group differences in antecedent risk factors, clinical features, and functional outcome.
results: The schizoaffective disorder group differed from the schizophrenia group on 
two measures only: they showed higher rates of suicidality (more suicide attempts, 
p < 0.01; more hospitalizations to prevent suicide, p < 0.01) and higher anxiety disorder 
comorbidity (p < 0.01).
conclusion: When schizoaffective disorder patients meet DSM criteria B and C for 
schizophrenia, they resemble schizophrenia patients on several measures used to 
assess validity. The increased rate of anxiety disorders and suicidality warrants clinical 
attention. Our data suggest that a more explicit definition of schizoaffective disorder 
reduces heterogeneity and may increase validity.
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inTrODUcTiOn
A recent meta-analysis of 50 studies comparing illness course and clinical outcomes in schizoaffec-
tive disorder, schizophrenia, and affective disorders reports the use of 10 different sets of diagnostic 
criteria for schizoaffective disorder (1). A review of the schizoaffective disorder literature revealed 
that patients with schizoaffective disorder had a better outcome than those with schizophrenia when 
ICD-10 criteria were used, but not when DSM-IV criteria were used (2).
Schizophrenia and schizoaffective disorder are defined by three domains of psychopathology: 
psychosis, mood symptoms, and functional impairment. Figure 1 plots the space defined by these 
three domains. We display the schizophrenia population as an ellipsoid constrained by two diag-
nostic criteria: decrease of function below the level achieved prior to illness onset (criterion B) and 
disturbances lasting for at least 6 months (criterion C). Mood symptoms may be present but are 
not major. Criteria B and C were added as gatekeepers during the DSM-III revision process, with 
the goal to exclude less severe cases and to increase the reliability and validity of schizophrenia (3).
FigUre 1 | Domains of psychopathology for schizophrenia and schizoaffective disorder. The symptom space for schizophrenia and schizoaffective 
disorder is defined by three domains: psychosis, mood symptoms, and functioning. Gray plane indicates baseline functional status. Heat map with hotter colors 
indicates worsening functional impairments. Ellipsoids demonstrate that schizophrenia occupies a constrained symptom space low on functioning, high on 
psychosis, and lower mood symptoms. By contrast, schizoaffective disorder is less constrained with potential for greater heterogeneity in functional status and 
degree of psychosis, though high on mood symptoms.
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By contrast, the schizoaffective disorder population occupies 
a considerably larger space, including patients with no func-
tional impairment and with lower levels of psychosis. Within 
these differently sized spaces, we diagnose schizophrenia three 
times more often than schizoaffective disorder (4). The result is 
a homogeneous schizophrenia population and a heterogeneous 
schizoaffective disorder population.
In an attempt to reduce diagnostic heterogeneity, Williams 
and McGlashan employed a stringent definition of schizoaffec-
tive disorder: patients met DSM-III diagnostic criteria for both 
schizophrenia and an affective disorder (5). Their schizoaffective 
disorder cohort did not differ from the schizophrenia cohort on 
a number of demographic, clinical, and outcome variables. They 
recommended that diagnostic criteria should include a specifica-
tion of whether schizoaffective disorder patients also meet full 
schizophrenia criteria, in order to reduce heterogeneity and 
minimize conflicting findings.
Here, we build on the study by Williams and McGlashan by 
comparing patients who met DSM-IV-TR criteria of schizoaffec-
tive disorder and schizophrenia, respectively. While the DSM-
IV-TR diagnoses schizophrenia and schizoaffective disorder 
share criterion A (delusions, hallucinations, disorganized speech, 
disorganized or catatonic behavior, and negative symptoms), 
the schizophrenia criterion B (marked functional impairment) 
and criterion C (continuous signs for at least 6  months) are 
permissible, but not required for a diagnosis of schizoaffective 
disorder (Table  1). This results in considerable heterogeneity, 
since the schizoaffective disorder population includes patients 
who do or do not meet schizophrenia criteria B and C.
In this study, we compared a group of schizoaffective dis-
order patients, who met DSM-IV-TR diagnostic criteria for 
schizoaffective disorder and also met DSM criteria B and C for 
schizophrenia, with a group of schizophrenia patients. The two 
groups were comparable in terms of sex, age, race, and duration 
of illness. We hypothesized that the groups would not differ with 
regard to antecedent risk factors, clinical features, and functional 
outcome.
sUBJecTs anD MeThODs
subjects
The sample for this study was taken from an ongoing data reposi-
tory at Vanderbilt University Medical Center, the Psychiatric 
Genotype/Phenotype Project. Subjects were recruited from 
inpatient units (61% of schizoaffective disorder sample, 54% 
of schizophrenia sample) and the outpatient clinic (23% of 
schizoaffective disorder sample, 23% of schizophrenia sample) 
of an academic medical center, and a local community mental 
health clinic with many Medicaid/Medicare patients (16% of 
schizoaffective disorder sample, 23% of schizophrenia sample). 
TaBle 1 | DsM-iV-Tr diagnostic criteria comparison.
criterion DsM-iV-Tr schizophrenia DsM-iV-Tr schizoaffective  
disorder
current schizoaffective  
disorder sample
A 2 or more of 5 symptoms Yes Yes Yes
B Marked functional impairment Yes ? Yes
C Continuous signs for at least 6 months Yes ? Yes
D Mood symptoms are brief Yes No No
E Not due to substance abuse/medical condition Yes Yes Yes
? represents the diagnostic uncertainty in the DSM-IV-TR schizoaffective disorder criteria regarding functional impairment and duration of illness.
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Subjects with a schizophrenia or schizoaffective disorder diag-
nosis were identified by medical record review and approached 
for participation in the repository. All patients enrolled were free 
of significant head injury, major medical or neurological illness, 
and active substance abuse or dependence. All study procedures 
were approved by the Vanderbilt University Institutional Review 
Board (Nashville, TN, USA), and written consent forms accom-
panied by comprehensive explanations of all study procedures 
were provided. Subjects were given monetary compensation for 
their participation.
The sample for the present study included all subjects who met 
diagnostic criteria for schizophrenia (N = 114) or schizoaffective 
disorder (N = 62) in the repository. Details concerning diagnostic 
criteria and review are outlined below.
clinical assessment
Study subjects were interviewed by Bachelors/Masters educated 
research assistants, who had completed intensive training, lasting 
a minimum of 3 months, by clinicians with expertise in conduct-
ing structured clinical interviews. Additional information from 
inpatient and outpatient medical records was obtained when 
available. All diagnoses were then reviewed and confirmed dur-
ing consensus diagnostic meetings with an expert psychiatrist 
(Stephan Heckers).
All subjects were interviewed with the Structured Clinical 
Interview for Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision (SCID-IV-TR) (6).
The reliability of the DSM-IV-TR schizoaffective disorder 
diagnosis is low, largely due to criterion C (mood episodes must 
be present for a “substantial” portion of the duration of psychosis) 
(7), which has a test–retest reliability kappa of 0.46 (8). In order to 
increase reliability of our assessment, we added the schizoaffective 
disorder module of the Diagnostic Interview for Genetic Studies 
(DIGS) (9). The DIGS module explicitly defines “substantial” as 
at least 30% mood episode overlap for the duration of psychosis. 
The majority of our schizoaffective disorder cohort (42 out of 
62 = 68%) also met DSM-5 criteria for schizoaffective disorder, 
which required that symptoms meeting criteria for a major mood 
episode were present for the majority (>50%) of the duration of 
the psychotic illness.
All of our schizophrenia and schizoaffective disorder patients 
met DSM-IV-TR criteria A–C for schizophrenia. All patients 
met not only the DSM-IV-TR criterion A but also the DSM-5 
criterion A for schizophrenia, i.e., they presented with at least 
two criteria A, at least one being delusions, hallucinations, or dis-
organized speech. Criterion B (social/occupational dysfunction) 
was defined as having functioning “markedly below the level 
achieved prior to the onset” in at least one of the following areas: 
(a) work, (b) personal relations, or (c) self-care. We considered 
an additional fourth area, (d) receiving social security disability 
payments for psychiatric illness, when making these judgments 
(evidence of significant functional impairment is necessary in 
order to receive social security disability payments).
Distress or impairment is also a diagnostic criterion for a major 
depressive episode (DSM-IV-TR and DSM-5 criterion B) or 
manic episode (DSM-IV-TR and DSM-5 criterion C). However, 
the functional impairment in schizophrenia is more severe and of 
longer duration, leading to a level of functioning below the level 
achieved prior to the onset. All schizoaffective disorder patients 
in this study had significant impairment in at least one of the four 
impairment areas, and over half had impairment across all areas 
(Table 2), making this a sample with a high degree of functional 
impairment. While the DSM-IV-TR criterion C for schizophrenia 
(continuous signs for at least 6 months) includes the prodromal, 
active, and residual phases of psychosis, all subjects in this study 
experienced at least 6 months of active psychosis in addition to 
any prodromal or residual phases.
For further characterization of the patient sample and to assess 
dimensions of current psychopathology, we complemented the 
SCID interview with the Global Assessment of Functioning 
(GAF) scale, the 17-item Hamilton Depression (HAM-D) rating 
scale, the Young Mania Rating Scale (YMRS), and the Positive 
and Negative Syndrome Scale (PANSS). We used the Wechsler 
Test of Adult Reading (WTAR) to assess premorbid IQ as an 
antecedent factor and the Screen for Cognitive Impairment in 
Psychiatry (SCIP) for the assessment of current cognitive func-
tion. We assessed functional outcome by collecting information 
about marital status, employment history, disability status, num-
ber of hospitalizations, and number of arrests during the SCID 
interview.
statistical analysis
We tested for group differences between the schizophrenia and 
schizoaffective disorder patients. Kolmogorov–Smirnov, skew-
ness, and Kurtosis tests for normality revealed that a number of 
our continuous variables were not normally distributed. We used 
non-parametric Mann–Whitney U tests to assess all continuous 
variables (age; duration of illness; CPZ equivalent and medica-
tion history; years of education; HAM-D, YMRS, PANSS, GAF, 
WTAR, and SCIP scores; medication history, arrests, psychiatric 
hospitalizations, hospitalizations to prevent suicide, and suicide 
attempts). Pearson chi-square analyses were used to assess 
categorical variables (sex, race, marital status, employment, 
disability, substance use disorders, and anxiety disorders).
TaBle 3 | sample characteristics.
schizoaffective disorder (N = 62) N schizophrenia (N = 114) N significance Different?
sex
% male 55 62 63 114 0.281 =
% female 45 37
age
Years 37.13 ± 11.95 62 36.59 ± 12.02 114 0.801 =
race
% White 68 62 54 114 0.224 =
% Black 27 40
% others 5 6
Duration of illness
Years 15.34 ± 10.12 48 16.58 ± 12.26 93 0.659 =
Medication
Current antipsychotic dose (CPZ equivalent) 589.14 ± 551.80 54 548.54 ± 303.54 107 0.634 =
Historical # of antipsychotics 4.80 ± 2.62 60 4.04 ± 2.30 112 0.061 =
Historical # of mood stabilizers 1.88 ± 1.44 60 1.22 ± 1.16 112 0.001* SZA > SZ*
Historical # of antidepressants 2.80 ± 2.43 60 2.04 ± 2.10 112 0.039 =
*Significance survived the Bonferroni correction for multiple comparisons (p < 0.008).
TaBle 2 | impairment.
impairment area One impairment  
(# of subjects)
Two impairments  
(# of subjects)
Three impairments  
(# of subjects)
Four impairments  
(# of subjects)
% impaired per area
Work 3 2 22 35 100
Personal relations 0 1 20 35 90
Disability 0 1 13 35 79
Self-care 0 0 11 35 74
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resUlTs
sample characteristics
Subjects were comparable with regard to sex, age, race, and 
duration of illness (Table 3). The groups had a similar history of 
treatment with antipsychotic and antidepressant drugs and were 
treated with a similar dosage of antipsychotic drugs at the time 
of the interview (Table 3). The schizoaffective disorder patients 
had been treated with a significantly greater number of mood 
stabilizers (U = 2,403.50, p < 0.01) (Table 3).
antecedent risk Factors
The schizoaffective disorder group did not differ from the schizo-
phrenia group on two measures of premorbid function associated 
with the risk for psychosis: premorbid intellectual function, as 
assessed with WTAR (U = 3,288.00, p > 0.05), and years of educa-
tion (U = 3,174.00, p > 0.05) (Table 4).
clinical Features
Both groups displayed moderate degrees of psychosis (PANSS 
scores) and few signs of mania (YMRS scores). The schizoaffec-
tive disorder patients were more depressed than the schizophre-
nia patients (HAM-D scores of 12.0 versus 8.5; U =  2,276.00, 
p <  0.01). Patients with schizoaffective disorder also reported 
more suicide attempts (U = 2,302.00, p < 0.01) and more hospi-
talizations to prevent suicide (U = 2,183.50, p < 0.01).
Both groups showed similar rates of substance use dis-
orders comorbidity [χ2(1, N =  176) =  0.54, p >  0.05], but the 
schizoaffective disorder group showed a higher rate of anxiety 
disorders [χ2(1, N = 176) = 16.32, p < 0.01], particularly PTSD 
[χ2(1, N = 176) = 14.03, p < 0.01].
The GAF scores did not differ between the two groups. The 
two groups also did not differ in their performance on the SCIP, 
which provides a measure of cognitive function at the time of the 
interview.
Functional Outcome Data
There was no difference between the two groups on a variety of 
measures of functional or clinical outcome, including history 
of marital status [χ2(1, N = 176) = 0.56, p > 0.05], number of 
arrests (U = 3,414.00, p > 0.05), percentage of patients employed 
[χ2(1, N =  176) =  0.001, p >  0.05], percentage qualifying for 
social security disability [χ2(1, N = 176) = 0.50, p > 0.05], or 
number of hospitalizations (U = 2,701.00, p > 0.05).
DiscUssiOn
Previous comparisons of schizoaffective disorder and schizo-
phrenia have been hampered by significant heterogeneity of 
the schizoaffective disorder samples. Here, we present results 
from a comparison of patients who met DSM criteria A–C for 
schizophrenia but differed with respect to meeting DSM criteria 
for schizoaffective disorder. When defined with this stringency, 
schizoaffective disorder and schizophrenia show similarities in 
antecedent risk factors, clinical features, and functional outcome. 
TaBle 4 | Validators.
schizoaffective disorder 
(N = 62)
N schizophrenia 
(N = 114)
N significance Different?
antecedent risk factors
IQ: Wechsler Test of Adult Reading 95.89 ± 16.82 61 94.48 ± 17.39 114 0.555 =
Years of education completed 13.25 ± 2.61 62 12.67 ± 2.26 114 0.257 =
clinical features
Global Assessment of Functioning 42.89 ± 12.99 56 42.48 ± 13.67 106 0.929 =
Cognition: Screen for Cognitive Impairment in Psychiatry total z-score −1.57 ± 1.05 57 −1.63 ± 1.03 110 0.807 =
Hamilton Depression score 11.95 ± 6.73 61 8.50 ± 6.58 113 0.001* SZA > SZ*
Young Mania Rating Scale score 6.65 ± 7.12 51 4.82 ± 4.50 98 0.302 =
Positive and Negative Syndrome Scale (PANSS) positive score 19.57 ± 6.68 61 20.45 ± 7.05 110 0.369 =
PANSS negative score 13.62 ± 4.85 61 16.61 ± 7.50 110 0.028 =
PANSS general score 33.57 ± 7.79 61 33.17 ± 8.28 110 0.722 =
PANSS total score 66.77 ± 15.02 61 70.24 ± 17.22 110 0.169 =
% comorbid substance abuse 66 62 61 114 0.463 =
% comorbid anxiety disorder 48 62 19 114 <0.001* SZA > SZ*
% PTSD 21 62 4 114 <0.001* SZA > SZ*
# of suicide attempts 4.58 ± 10.98 62 1.08 ± 2.43 114 <0.001* SZA > SZ*
# of hospitalizations to prevent suicide 3.05 ± 4.91 56 1.57 ± 4.24 110 0.001* SZA > SZ*
Functional outcome
% impaired marital status 89 62 92 114 0.454 =
% employed 18 62 18 114 0.974 =
% disability 79 62 83 114 0.480 =
# of hospitalizations 10.18 ± 11.08 57 9.69 ± 21.53 110 0.142 =
# of arrests 3.63 ± 12.88 62 3.07 ± 7.16 113 0.774 =
*Significance survived the Bonferroni correction for multiple comparisons (p < 0.003).
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However, the schizoaffective disorder patients were more 
depressed, reported greater suicidality, and showed increased 
rates of anxiety disorders, especially PTSD. Trauma shapes the 
phenotype of psychosis (10), but whether this affects schizoaffec-
tive disorder patients more than schizophrenia patients warrants 
further examination.
These results differ from the conventional view that schiz-
oaffective disorder is a more benign clinical condition than 
schizophrenia (11). But they are supportive of recent reports that 
inconsistent clinical characterization of schizoaffective disorder, 
including the use of multiple diagnostic criteria, has led to poor 
consensus across studies (1, 2). To our knowledge, only one 
previous study restricted the schizoaffective disorder sample to 
those patients who also met full schizophrenia criteria, and the 
authors reported a comparable clinical picture for their two study 
cohorts (5). Employing a similarly stringent set of criteria, our 
results indicate comparable clinical and functional outcomes for 
schizoaffective disorder and schizophrenia.
Schizoaffective disorder has been defined in the context of a 
categorical diagnostic system, but there is compelling reason to 
redefine the disorder in the context of a dimensional system (12). 
The two patient groups in our study were comparable on the 
majority of measures but showed higher rates of anxiety disorders 
and suicidality. A mixed categorical (schizophrenia criteria A–C) 
and dimensional (mood and anxiety symptoms) definition of 
schizoaffective disorder would be a reasonable alternative to the 
current DSM-5 definition of schizoaffective disorder. Psychotic 
patients can then be assessed for affective symptoms without 
imposing a categorical distinction between schizophrenia or 
schizoaffective disorder. Levitt and Tsuang suggested subtyping 
of schizoaffective disorder patients based on the polarity of mood 
symptoms (depressive and manic subtypes) (13), as is present 
in the DSM-IV-TR and ICD-10 classifications (14). However, 
McGlashan and Williams suggested that attention should be 
paid instead to how “schizophrenic” the schizoaffective disorder 
clinical picture is, and that this will be the strongest predic-
tor of outcome (15). This suggestion is similar to the “Mainly 
Schizophrenic” subtype in the RDC classification, which requires 
the presence of psychosis for at least one week outside of a mood 
episode (16), and the optional specification of psychosis outside 
of mood symptoms in the ICD-10 classification.
Schizoaffective disorder is a common clinical diagnosis 
(17), despite numerous concerns regarding validity, reliability, 
and clinical utility (7, 18–21). As diagnostic criteria utilized in 
schizoaffective disorder research greatly vary, the findings of the 
present study emphasize the importance of using well-defined 
diagnostic criteria when examining schizoaffective disorder. 
Defining schizoaffective disorder with additional criteria for 
duration of psychotic episodes and functional impairment will 
improve the reproducibility of schizoaffective disorder research. 
While the DSM-5 criterion C for schizoaffective disorder has 
become more stringent, it will decrease prevalence rates, but 
not necessarily the diagnostic heterogeneity of schizoaffective 
disorder reported here.
We were able to examine only one subgroup of schizoaffec-
tive disorder patients, which is a significant limitation of this 
study. When reviewing our cohort of chronic psychosis patients 
eligible for inclusion in the study, only 1 of 177 met schizoaf-
fective disorder criteria but not schizophrenia criteria B and C. 
This might indicate a greater prevalence of the schizoaffective 
disorder subpopulation examined here; however, we need to 
consider an ascertainment bias since our patient sample was 
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primarily recruited from psychiatric inpatient units. It is an 
essential next step to compare schizoaffective disorder patients, 
who do not meet schizophrenia B and C criteria, with the two 
groups considered here and with a group of psychotic bipolar 
disorder patients. Another limitation of our study is the narrow 
set of clinical and functional outcome data. Future studies should 
explore the antecedent, concurrent, and predictive validators of 
schizoaffective disorder more thoroughly.
Schizoaffective disorder has been considered a better outcome 
diagnosis when compared with schizophrenia, but the literature 
has been inconclusive. The present study supports the need 
for a more detailed clinical characterization of schizoaffective 
disorder patients for treatment and endophenotype studies, thus 
reducing heterogeneity and increasing reliability and validity.
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